Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sodium algorithm Clear all
Completed Not applicable Interventional Results available

The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma

NCT01050153
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Dalteparin sodium, Dalteparin sodium/aspirin
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Results available

BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH

NCT02314026
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
Suspected NASH BreathID test with 13C-Octanoate, Suspected NASH Breath test with 13C Methacetin
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Chicago, Illinois • Forts Sam Houston, Texas • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Dietary Sodium Supplementation on Growth & Intestinal Microbiome

NCT05546814
View directory record Official record
Conditions
Preterm Birth
Interventions
Sodium algorithm
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
25 Weeks to 30 Weeks
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Results available

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

NCT00797823
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin, Asp(B28)-, Glucagon, Placebo
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 7, 2026, 8:35 AM EDT
Recruiting Not applicable Interventional

Sodium and Milk Fortification Evaluation of Body Composition Among Very Preterm Infants

NCT07562997
View directory record Official record
Conditions
Very Preterm and Extremely Preterm Birth
Interventions
Urine sodium testing, Serum sodium testing, Milk fortification
Diagnostic Test · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
0 Days to 14 Days
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Cincinnati, Ohio • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 7, 2026, 8:35 AM EDT
Terminated Phase 2 Interventional Results available

Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial

NCT03259165
View directory record Official record
Conditions
Heart Failure, Heart Failure Acute, Acute Cardiac Failure, Acute Cardiac Pulmonary Edema
Interventions
Nitrates, Loop Diuretics
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Indianapolis, Indiana • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 7, 2026, 8:35 AM EDT
Not yet recruiting Not applicable Interventional

Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction

NCT05464940
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Intravenous caffeine, Masked Placebo
Other
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
21 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Loma Linda, California • Overland Park, Kansas • Independence, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 7, 2026, 8:35 AM EDT
Recruiting Phase 2 Interventional

A Study of Blood Pressure Control During Cancer Treatment

NCT06023576
View directory record Official record
Conditions
Breast Cancer, Cardiotoxicity
Interventions
antihypertensive medications, Blood pressure measurement, Echocardiogram, Symptom-limited cardiopulmonary exercise test, Quality of Life Measures, Biomarkers
Other · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 7, 2026, 8:35 AM EDT
Completed No phase listed Observational

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

NCT05096039
View directory record Official record
Conditions
Heart Failure
Interventions
Sacubitril/valsartan, ACEI or ARB and no sacubitril/valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,614,719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Memory & Conditioning Under Anesthesia

NCT04062123
View directory record Official record
Conditions
Anesthesia, Pain
Interventions
Dexmedetomidine, Propofol, Fentanyl, Peripheral Nerve Stimulation, Placebo
Drug · Device
Lead sponsor
Keith M Vogt
Other
Eligibility
18 Years to 39 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Front-of-Package Nutrition Labels

NCT06516627
View directory record Official record
Conditions
Nutrition, Food Selection, Food Preferences, Dietary Habits, Healthy Diet
Interventions
Positive Labels, Spectrum Labels, FDA High In Labels, FDA Traffic Light Labels
Behavioral
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
18 Years and older
Enrollment
5,638 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Phase 2 Interventional Results available

Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound

NCT03245255
View directory record Official record
Conditions
Cardiac Catheterization, Blood Pressure, Heart Ventricles, Echocardiography, Heart Failure
Interventions
Sonazoid
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

PeriOperative ISchemic Evaluation-3 Trial

NCT03505723
View directory record Official record
Conditions
Perioperative Bleeding, Venous Thrombosis, Arterial Thrombosis
Interventions
Tranexamic Acid, Placebo (Saline), Perioperative hypotension-avoidance strategy, Perioperative hypertension-avoidance strategy
Drug · Other
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
9,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
12
States / cities
New Haven, Connecticut • Weston, Florida • New York, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Phase 4 Interventional Results available

Physiologic Approach to Sodium Supplementation in Premature Infants

NCT03889197
View directory record Official record
Conditions
Postnatal Growth Disorder
Interventions
Sodium supplementation guided by urine sodium concentration algorithm
Drug
Lead sponsor
Indiana University
Other
Eligibility
7 Days to 16 Days
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 7, 2026, 8:35 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants

NCT01360450
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine HCL, saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Days to 90 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 7, 2026, 8:35 AM EDT
Active, not recruiting Not applicable Interventional

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT01652092
View directory record Official record
Conditions
SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Interventions
Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Melphalan, Alemtuzumab 0.2 mg, Fludarabine phosphate 30 mg, MESNA
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 50 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 7, 2026, 8:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

NCT06046560
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes
Interventions
SGLT2 inhibitor, GLP-1 RA, Education-First
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
27 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 7, 2026, 8:35 AM EDT